# PF-06804103 Dose Escalation in HER2 Positive and Negative (Negative Only in Part 2) Solid Tumors

> **NCT03284723** · PHASE1 · TERMINATED · sponsor: **Pfizer** · enrollment: 95 (actual)

## Conditions studied

- Breast Neoplasms

## Interventions

- **DRUG:** PF-06804103
- **DRUG:** PF-06804103 + Palbociclib +Letrozole

## Key facts

- **NCT ID:** NCT03284723
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-11-01
- **Primary completion:** 2021-08-31
- **Final completion:** 2021-08-31
- **Target enrollment:** 95 (ACTUAL)
- **Why stopped:** The trial was terminated based on the stage in drug development and assessment of PF-06804103 relative to the leading external competition. The decision was not due to a safety concern.
- **Last updated:** 2024-09-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03284723

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03284723, "PF-06804103 Dose Escalation in HER2 Positive and Negative (Negative Only in Part 2) Solid Tumors". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03284723. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*